Digital tools are a key to shortening the development of active pharmaceutical ingredients and thus market-ready drugs and therapies.

Big data and artificial intelligence (AI) can significantly accelerate many processes and make them more efficient. The Paris, France-based start-up Iktos is developing a proprietary AI technology for lig­and and structure-based de novo drug design, focusing on multi parametric optimization (MPO). Yann Gaston-­Mathé, co-founder and CEO of Iktos, explains the company’s technologies and pro­vides an outlook on the further devel­opment of the company. Read the full article here.